BrianBahmanBorgMD

Clinical Trials

• Assess Safety and Efficacy of ELAD (Extracorporeal Liver Assist System) in Subjects With Alcohol-Induced Liver Failure Start of enrollment: 2013 Feb 01

  Completed

  Phase 3

• Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis Start of enrollment: 2014 Dec 26

  Terminated

  Phase 4

• Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis Start of enrollment: 2015 Jun 01

  Completed

  Phase 2

• Study of Oral Treatments for Hepatitis C Start of enrollment: 2016 Jun 01

  Completed

  Phase 4

• Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH) Start of enrollment: 2016 Oct 24

  Terminated

  Phase 2

• Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC) Start of enrollment: 2016 Nov 28

  Completed

  Phase 2

• Evaluation of HepQuant SHUNT to Assess Liver Disease; Substudy Within GS-US-416-2124 Start of enrollment: 2016 Jul 31

  Withdrawn

  Early Phase 1

• Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects Start of enrollment: 2017 Apr 20

  Completed

  Phase 3

• The HepQuant SHUNT Test for Monitoring Liver Disease and Treatment Effects by Measuring Liver Function and Physiology Start of enrollment: 2017 Dec 08

  Terminated

  Phase 2

• Join now to see all